Jinwon Life Sciences Subsidiary VGXI "Officially Invited to Participate in JP Morgan Healthcare Conference"

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 5th that its subsidiary VGXI has been officially invited to participate in the 41st JP Morgan Healthcare Conference held in San Francisco, USA, from the 9th to the 12th, following last year.

Started in 1983, the JP Morgan Healthcare Conference is the world's largest pharmaceutical and bio event hosted by the global investment bank JP Morgan Chase, gathering healthcare companies worldwide as well as venture capital and private equity investment firms. This year, it is reported that over 1,500 global pharmaceutical and bio companies and investors from more than 50 countries will attend, and the event, which was held online for the past two years due to the COVID-19 pandemic, will be conducted offline.

Park Younggeun, CEO of GeneOne Life Science, said, "VGXI greatly expanded its high-quality plasmid DNA contract development and manufacturing organization (CDMO) capabilities by completing a new factory last October," adding, "Through participation in the event, we will showcase VGXI’s skilled production technology and differentiated high-quality product manufacturing services to potential clients and investors."

He continued, "Through business meetings with multinational pharmaceutical companies and global investors, we plan to seek opportunities for technology transfer, joint development discussions, and partnership agreements related to our company’s R&D pipeline, focusing on expanding business opportunities."

This content was produced with the assistance of AI translation services.